LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr

The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.

Jubilant Pharmova posts Q1FY23 consolidated PAT at Rs. 47.04 Cr

The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.

PIB: Quality control of Ayush drugs

PIB: Budget allocation and utilization of funds under National Ayush Mission

The total budget of Rs. 3119.46 crores has been allocated/ released as a central share to States/UTs since the inception of the scheme and they have reported an expenditure of Rs. 2290.20 crores.

PIB: Development of Ayush entrepreneurship

Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.

Health Minister Mandaviya addresses inaugural ceremony of training programme for senior administrative medical officers of CGHS

Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar

Thyrocare Technologies posts Q1FY23 consolidated PAT at Rs. 21.73 Cr

The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.

Ayush Minister Sonowal inaugurates Ayush Building Complex in Navi Mumbai

Steps afoot to make RRIH & RRIUM as a Centres of Excellence for Allergic Disorder and for Regimental Therapy respectively

Cipla posts Q1FY23 consolidated PAT at Rs. 686.40 Cr

he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.